National Association of Testing Authorities, Australia
Scope of Accreditation
Royal Hobart Hospital
Site
Pathology Services incorporating Pathology South
Accreditation No.
3036
Site No.
3029
Date of Accreditation
26 Nov 1990
Address
48 Liverpool Street
Hobart, TAS 7000
Australia
Contact
Availability
Services available to external clients
Supervision
GX (General)
Scope of Accreditation
Anatomical Pathology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Anatomical pathology - Cytopathology - Cervical cytological investigation for abnormalities, precancerous or cancerous changes or conditions | Cervical smear; Liquid based cytology specimens from cervix | Cytological examination; Review and reporting of cervical cytological material |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations of body fluids, exudates, washings and brushings from non-squamous mucosal sites for the detection of malignancy | Other body fluids | Cytological examination; Review and reporting of cytology samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations of nipple discharge or smears from squamous mucosal sites for the detection of cancerous or precancerous changes | Skin smears | Cytological examination; Review and reporting of cytology samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations on samples obtained via fine needle aspiration biopsy | Fine needle aspirates (FNA) | Cytological examination; Review and reporting of fine needle aspiration samples |
| Anatomical pathology - Tissue pathology - Examination of biopsy material | Formalin-fixed tissue; Fresh tissue | Review and reporting of biopsy material to identify or exclude morphological abnormalities |
| Anatomical pathology - Tissue pathology - Gene probes using paraffin in situ hybridisation techniques (chromogenic/silver) | Formalin-fixed paraffin-embedded (FFPE) tissues | Detection of nucleic acid targets - Various |
| Anatomical pathology - Tissue pathology - Immediate frozen section diagnosis | Fresh tissue | Intra-operative consultation and examination of biopsy material |
| Anatomical pathology - Tissue pathology - Immunohistochemical (immunofluorescence) investigation | Fresh tissue | Detection of antigenic targets - Various |
| Anatomical pathology - Tissue pathology - Immunohistochemical investigation | Formalin-fixed paraffin-embedded (FFPE) tissues | Detection of antigenic targets - Various |
Core Laboratory
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Analysis of drugs for toxicological (non-legal) purposes and ingested or absorbed toxic chemicals | Urine | 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP); Amphetamines; Benzodiazepines; Buprenorphine; Cannabis; Cocaine; Opiates; Oxycodone |
| Chemical pathology - Detection and/or quantitation of drugs for therapeutic monitoring | Blood | Cyclosporin; Methotrexate; Tacrolimus |
| Plasma; Serum | Amikacin; Gentamicin (cidomycin, septopal, genticyn, garamycin); Tobramycin; Vancomycin | |
| Carbamazepine; Digoxin; Ethanol; Lithium; Paracetamol (acetaminophen); Phenobarbitone; Phenytoin (dilantin); Salicylate; Theophylline; Valproate (valproic acid, epilim) | ||
| Chemical pathology - Detection and/or quantitation of tumour markers | Other body fluidsAscitic fluid; Pleural fluid | CA125 antigen (CA125); CA15-3 antigen (CA15-3); CA19-9 antigen (CA19-9); Carcinoembryonic antigen (CEA); Human chorionic gonadotropin (hCG); α-Fetoprotein (AFP) |
| Plasma; Serum | β2-Microglobulin (B2M) | |
| CA125 antigen (CA125); CA15-3 antigen (CA15-3); CA19-9 antigen (CA19-9); Carcinoembryonic antigen (CEA); Prostate specific antigen (PSA); Prostate specific antigen (PSA) fractions and derived index; α-Fetoprotein (AFP); β2-Microglobulin (B2M) | ||
| Chemical pathology - Determination of hormones and hormone binding proteins (other than thyroid function tests) | Plasma; Serum | Procalcitonin |
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
| Chemical pathology - Further investigation of cardiac function | Plasma; Serum | N-Terminal-pro b-type natriuretic peptide (NT-proBNP); Troponin T |
| Chemical pathology - Further investigation of lipid profiles for diagnosis of types III and IV hyperlipidaemia | Plasma; Serum | HDL - Quantitation |
| Chemical pathology - Further investigation of renal and/or hepatic function | Plasma; Serum | Caeruloplasmin; Haptoglobins; α1-Antitrypsin |
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Ascitic fluid | Albumin; Bilirubin - Total; Calcium - Total; Chloride; Cholesterol - Total; Creatinine; Glucose; Lactate; Lactate dehydrogenase (LDH); Lipase; Phosphate; Potassium; Protein - Total; Sodium; Triglycerides; Urate; Urea |
| Cerebrospinal fluid (CSF) | Glucose; Lactate dehydrogenase (LDH); Protein - Total | |
| Drainage fluid | Creatinine; Lipase | |
| Peritoneal dialysis fluid | Creatinine; Glucose; Urea | |
| Plasma; Serum | Alanine aminotransferase; Albumin; Alkaline phosphatase; Ammonia; Aspartate aminotransferase; Bicarbonate; Bilirubin - Any fractions; Bilirubin - Total; C-reactive protein (CRP); Calcium - Total; Chloride; Cholesterol - Total; Creatine kinase; Creatinine; Glucose; Lactate; Lactate dehydrogenase (LDH); Lipase; Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Triglycerides; Urate; Urea; γ-Glutamyltransferase | |
| Plasma; Serum; Urine | Osmolality | |
| Pleural fluid | Albumin; Bilirubin - Total; Calcium - Total; Chloride; Cholesterol - Total; Creatinine; Glucose; Lactate; Lactate dehydrogenase (LDH); Lipase; Phosphate; Potassium; Protein - Total; Sodium; Triglycerides; Urate; Urea | |
| Urine | Albumin; Calcium - Total; Chloride; Creatinine; Glucose; Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Urate; Urea | |
| Chemical pathology - Investigation for folate deficiency | Serum | Folate |
| Chemical pathology - Iron studies | Plasma; Serum | Ferritin; Iron; Transferrin |
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Bilirubin - Total; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
| Chemical pathology - Quantitation of vitamins | Serum | Retinol (vitamin A); Tocopherol (vitamin E) |
| Cobalamin (vitamin B12); Holotranscobalamin (active vitamin B12) | ||
| Haematology - Bone marrow examination | Bone marrow | Examination of aspirated material |
| Haematology - Foetal haemoglobin in maternal circulation | Blood | Detection and quantitation of foetal red cell antigens |
| Haematology - Full blood examination | Blood | Differential number; Morphology; Reticulocytes |
| Differential number; Erythrocyte count (red blood cell count, RBCC); Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Leucocyte count (white blood cell count, WBCC); Platelet count; Red blood cell index or indices; Reticulocytes | ||
| Haematology - Haemostasis related analysis (including special coagulation testing and platelet function tests) | Plasma | Factor II; Factor IX; Factor V; Factor VII; Factor VIII; Factor X; Factor XI; Factor XII; Protein C and protein S |
| Platelet aggregation | ||
| Activated partial thromboplastin time (APTT); Anti-thrombin III; D-dimer; Fibrinogen; International normalised ratio (INR); Lupus anticoagulant; Mixing studies - APTT; Prothrombin time (PT) | ||
| Plasma; Serum | Heparin induced thrombotic thrombocytopenia (HITT) | |
| Anti-Xa - Apixaban; Anti-Xa - Dabigatran; Anti-Xa - Rivaroxaban; Anti-Xa activity; Factor VIII inhibitor | ||
| Haematology - Limited blood examination | Blood | Erythrocyte (RBC) sedimentation rate (ESR) |
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Plasma; Serum | Rheumatoid factor |
| Immunopathology - Quantitation of complement proteins | Plasma; Serum | Complement components C3 and C4 |
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Serum | Detection and quantitation of free kappa and free lambda light chains |
| Immunopathology - Quantitative investigations of immunoglobulins and immunoglobulins subclasses | Plasma; Serum | Total immunoglobulin A; Total immunoglobulin G; Total immunoglobulin M |
| Infertility and pregnancy tests including assisted reproductive technology - Diagnosis or follow up of threatened abortion and/or diagnosis of ectopic pregnancy | Plasma; Serum | Human chorionic gonadotropin (hCG) - Quantitative total |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (protozoan parasites) | Blood | Malaria |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Serum | Infectious mononucleosis |
Cytogenetics and Molecular Medicine
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Anatomical pathology - Cytopathology - Testing for the National Cervical Screening Program | Liquid based cytology specimens from cervix | Human papilloma virus (HPV); Cytological examination; Review and reporting of cervical cytological material |
| Self-collected vaginal swabs | Human papilloma virus (HPV) | |
| Cytogenetics - Detection of defined, balanced and/or unbalanced chromosomal abnormalities by in situ hybridisation techniques | Blood; Bone marrow; Other tissues - Malignant | Cytogenetic analysis and reporting |
| Cytogenetics - Molecular karyotype (SNP microarray) detection of unbalanced chromosome abnormalities | Blood; Bone marrow; Other tissues - Malignant | Cytogenetic analysis and reporting |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (bacteria) | Blood; Cerebrospinal fluid (CSF) | Haemophilus influenzae; Listeria monocytogenes; Neisseria meningitidis; Streptococcus pneumoniae |
| Neisseria meningitidis | ||
| Blood; Cerebrospinal fluid (CSF); Nasopharyngeal aspirate; Nasopharyngeal swabs; Sputum | Bordetella pertussis | |
| Dry swabs; Urine | Chlamydia trachomatis; Mycoplasma genitalium; Neisseria gonorrhoeae | |
| Faeces | Aeromonas spp.; Campylobacter spp.; Clostridioides difficile; Escherichia coli - Enteroinvasive (EIEC); Escherichia coli; Escherichia coli STEC stx1/stx2; Salmonella spp.; Shigella spp.; Yersinia enterocolitica; Yersinia pestis; Yersinia pseudotuberculosis | |
| Clostridioides difficile | ||
| Genital swabs; Urine | Macrolide resistant Mycoplasma genitalium | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (mycobacteria) | Blood; Cerebrospinal fluid (CSF) | Mycobacterium tuberculosis |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (protozoan parasites) | Faeces | Cryptosporidium spp.; Entamoeba histolytica; Giardia lamblia |
| Genital swabs; Urine | Trichomonas vaginalis | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (viruses) | Blood; Cerebrospinal fluid (CSF) | Enterovirus; Herpes simplex virus (HSV); Human parechovirus; Varicella zoster virus (VZV) |
| Blood; Cerebrospinal fluid (CSF); Dry swabs; Tissues; Urine | Cytomegalovirus (CMV); Herpes simplex virus (HSV); Varicella zoster virus (VZV) | |
| Faeces | Adenovirus; Astrovirus; Norovirus; Rotavirus; Sapovirus | |
| Liquid based cytology specimens | Human papilloma virus (HPV) | |
| Nasal swabs; Nasopharyngeal aspirate; Urine | Measles virus | |
| Nasopharyngeal aspirate; Nasopharyngeal swabs; Sputum | Adenovirus; Human metapneumovirus; Influenza A virus; Influenza B virus; Parainfluenza virus type 1/2/3/4; Respiratory syncytial virus (RSV) A/B | |
| Nasopharyngeal swabs; Oropharyngeal swabs | Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV) A/B; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Influenza A virus; Influenza B virus; Respiratory syncytial virus (RSV) A/B; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Nasopharyngeal swabs; Oropharyngeal swabs; Sputum | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Microbiology - Molecular biology - Quantitation of microbial nucleic acids | Plasma | Human immunodeficiency virus (HIV) RNA viral load |
| Plasma; Serum | Hepatitis C virus (HCV) viral load | |
| Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted genes | Blood | Factor V Leiden; Prothrombin variant |
| Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted panels for inherited (germline) DNA/RNA changes | Blood | Hereditary haemochromatosis |
| Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted genes | Blood; Bone marrow | Quantitative calculation of p190 and p210 positive BCR::ABL1 transcripts |
| JAK2 V617F mutation | ||
| Qualitative calculation of p190 and p210 positive BCR::ABL1 transcripts; t(9;22) BCR-ABL gene rearrangement | ||
| Molecular genetics - Genetic testing for chimerism and mosaic gene variants (cancer and somatic mosaicism) - Targeted panels for non-inherited (somatic) DNA/RNA changes | Blood | Myeloproliferative neoplasmsVEXAS syndrome |
Emergency Department
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Bilirubin - Total; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Endocrinology Laboratory
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Detection and/or quantitation of tumour markers | Plasma; Serum | Thyroglobulin |
| Serum | Chromogranin A - Gen I | |
| Chemical pathology - Determination of hormones and hormone binding proteins (other than thyroid function tests) | Plasma | Renin |
| Plasma; Serum | Pancreatic polypeptide (PP); Vasoactive intestinal peptide (VIP) | |
| Insulin-like growth factor 1 (IGF-1, somatomedin C) | ||
| 17α-Hydroxyprogesterone | ||
| Glucagon | ||
| Adrenocorticotropic hormone (ACTH); C-peptide; Cortisol; Dehydroepiandrosterone sulfate (DHEAS); Follicle stimulating hormone (FSH); Gastrin; Growth hormone; Insulin; Luteinising hormone (LH); Oestradiol; Parathyroid hormone (PTH); Progesterone; Prolactin; Sex hormone binding globulin (SHBG); Testosterone | ||
| Plasma; Serum; Urine | Aldosterone | |
| Serum | 11-Deoxycortisol | |
| Urine | Cortisol | |
| Chemical pathology - Quantitation of vitamins | Plasma; Serum | 25-Hydroxyvitamin D |
| Chemical pathology - Tests for thyroid function | Plasma; Serum | Thyroid stimulating hormone (TSH); Thyroid stimulation immunoglobulins; Thyroxine (T4) - Free; Triiodothyronine (T3) - Free |
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Serum | Anti-glutamic acid decarboxylase antibodies (GAD); Anti-insulin receptor antibodies (IR) |
| Anti-thyroglobulin antibodies (Tg); Anti-thyroid peroxidase antibodies (TPO) | ||
| Anti-thyrotropin receptor antibodies (TSHR) | ||
| Immunopathology - Quantitative and/or qualitative investigation of glycoproteins | Plasma; Serum | Free α-glycoprotein sub-unit |
| Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted genes | Blood | Multiple endocrine neoplasia type 1 (MEN1) |
Immunohaematology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Haematology - Investigation of haemolysis | Blood | Direct antiglobulin test (DAT, direct Coombs test) |
| Cold agglutinins | ||
| Immunohaematology - Blood group antibody detection | Blood | Other blood group systems; Rh phenotypes |
| Immunohaematology - Blood grouping | Blood | ABO; RhD |
| Immunohaematology - Determination of compatibility of blood donor units | Blood | Direct antiglobulin test (DAT, direct Coombs test); Examination for blood group antibodies; Group checks of patient and donor; Identification of detected antibodies |
| Immunohaematology - Identification and quantitation of blood group antibodies | Blood | Other blood group antibodies; Red blood cell phenotyping; Rh |
| Antibody absorption | ||
| Antibody elution | ||
| Plasma | Antibody titration | |
| Immunohaematology - Investigation of blood transfusion reactions | Blood; Blood products; Plasma | Antibodies; Contamination - Microbiological; Direct antiglobulin test (DAT, direct Coombs test); Examination for blood group antibodies; Group checks of patient and donor; Identification of detected antibodies |
| Immunohaematology - Issue and release of blood and blood product for transfusion | Blood; Cryoprecipitate; Fresh frozen plasma (FFP); Platelets | Issue and release of blood and blood products for transfusion |
| Immunohaematology - Storage and distribution of blood and blood components | Blood products | Issue and release of blood and blood products for transfusion |
Intensive Care Unit
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Bilirubin - Total; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Creatinine; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Maternity
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Bilirubin - Total; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Microbiology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Microbiology - Bacteriology - Detection of pathogenic bacteria | Blood | Bacteria; Pathogenic microorganisms |
| Blood; Cerebrospinal fluid (CSF); Faeces; Fluids; General swabs; Genital swabs; Sputum; Synovial fluid; Tissues; Urine | Bacteria; Pathogenic identification and antibiotic susceptibility | |
| Bacteria; Pathogenic identification and antibiotic susceptibility | ||
| Bacteria; Pathogenic identification and antibiotic susceptibility | ||
| Bacteria; Pathogenic microorganisms | ||
| Bacteria; Pathogenic identification and antibiotic susceptibility | ||
| Blood; Cerebrospinal fluid (CSF); Fluids; General swabs; Sputum; Synovial fluid; Tissues; Urine | Bacteria; Casts; Crystals; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC) | |
| Faeces | Clostridioides difficile toxin | |
| Helicobacter pylori | ||
| Urine | Glucose; Proteins | |
| Legionella antigen; Streptococcus pneumoniae | ||
| Microbiology - Environmental investigations and/or infection control (Clinical non-human testing) | Blood transfusion bags; Gastrointestinal endoscopes; Vascular catheter tips | Bacterial growth - Sterility |
| Environmental swabs | Bacterial organism identification - Methicillin-resistant Staphylococcus aureus (MRSA); Bacterial organism identification - Vancomycin-resistant Enterococcus (VRE) | |
| Spore strips | Bacterial growth - Sterility | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (bacteria) | Bacterial isolates; Blood | Staphylococcus aureus; Carbapenem resistant Enterobacteriaceae (CRE); Methicillin resistant Staphylococcus aureus (MRSA); Vancomycin resistant Enterococci (VRE) |
| Blood | Acinetobacter baumannii; Haemophilus influenzae; Klebsiella oxytoca; Klebsiella pneumoniae; Klebsiella pneumoniae carbapenemase (KPC); Listeria monocytogenes; Neisseria meningitidis; Plesiomonas shigelloides; Proteus spp.; Pseudomonas aeruginosa; Salmonella spp.; Serratia marcescens; Staphylococcus aureus; Staphylococcus spp.; Streptococcus agalactiae (Streptococcus group B); Streptococcus pneumoniae; Streptococcus pyogenes; Streptococcus spp.; Vibrio cholerae; Vibrio spp.; Yersinia enterocolitica; MecA gene; Van A/B | |
| Faeces | Campylobacter spp.; Clostridium difficile toxin A; Clostridium difficile toxin B; Enterobacter cloacae complex; Enterobacteriaceae; Enterococcus spp.; Escherichia coli - Enteroaggregative (EAEC); Escherichia coli - Enteroinvasive (EIEC); Escherichia coli - Enteropathogenic (EPEC); Escherichia coli; Escherichia coli O157; Escherichia coli STEC stx1/stx2 | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (mycobacteria) | Respiratory specimens | Mycobacterium tuberculosis |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (protozoan parasites) | Faeces | Cryptosporidium spp.; Cyclospora cayetanensis; Entamoeba histolytica; Giardia lamblia |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (viruses) | Faeces | Norovirus |
| Adenovirus; Astrovirus; Norovirus; Rotavirus; Sapovirus | ||
| Liquid based cytology specimens | Human papilloma virus (HPV) | |
| Serum | Hepatitis B virus (HBV) viral load | |
| Microbiology - Mycobacteriology - Detection and identification of mycobacteria | Cerebrospinal fluid (CSF); Other body fluids; Respiratory specimens; Sputum; Tissues; Urine | Mycobacteria identification |
| Mycobacteria identification | ||
| Mycobacteria identification | ||
| Microbiology - Mycology - Detection, isolation and/or identification of yeasts and/or fungal elements | Cerebrospinal fluid (CSF); Fluids; General swabs; Nails; Skin scrapings; Sputum; Tissues; Urine | Fungi identification; Yeasts identification |
| Fungi identification; Yeasts identification | ||
| Yeast susceptibility | ||
| Cerebrospinal fluid (CSF); Serum | Cryptococcus antigen | |
| Microbiology - Parasitology - Detection of ova, cysts and parasites | Faeces | Cysts; Ova; Parasites |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Serum | Schistosoma mansoni |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) IgG antibody | ||
| Syphilis Treponema pallidum antibody | ||
| Syphilis Treponema pallidum antibody | ||
| Fluorescent Treponemal antibody | ||
| Helicobacter pylori; Hepatitis C virus (HCV); Measles virus; Mumps virus; Varicella zoster virus (VZV) | ||
| Cytomegalovirus antibody (anti-CMV) IgG; Cytomegalovirus antibody (anti-CMV) IgM; Epstein-Barr virus IgG antibody; Epstein-Barr virus IgM antibody; Epstein-Barr virus nuclear antigen; Hepatitis A virus antibody (anti-HAV) - IgG; Hepatitis A virus antibody (anti-HAV) - IgM; Hepatitis B virus (HBV); Hepatitis B virus core antibody (anti-HBc) - IgM; Hepatitis B virus core antibody (anti-HBc) - Total; Hepatitis B virus surface antibody (anti-HBs); Hepatitis B virus surface antigen (HBs Ag); Hepatitis C virus (HCV); Human immunodeficiency virus type 1/2 (HIV-1/2) 1/2 antibodies; Rubella IgG antibody; Syphilis Treponema pallidum antibody; Toxoplasma gondii IgG antibody; Toxoplasma gondii IgM antibody |
Neonatal Intensive Care Unit
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Bilirubin - Total; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Neurosurgery
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Bilirubin - Total; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Operating Theatres
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Quantitation of blood gases and other measurements (performed on the same specimen) | Blood | Bilirubin - Total; Calcium - Ionised; Carboxyhaemoglobin; Chloride; Glucose; Haemoglobin (Hb); Lactate; Methaemoglobin (MetHb); Oxyhaemoglobin; Partial pressure of carbon dioxide (pCO2); Partial pressure of oxygen (PO2); Potassium; Sodium; pH |
Paediatric Diabetic Clinic
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
Special Chemistry
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Detection and/or quantitation of drugs for therapeutic monitoring | Plasma | Clozapine |
| Chemical pathology - Detection of faecal occult blood | Faeces | Blood |
| Chemical pathology - Dynamic tests | Sweat | Sweat chloride |
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Cerebrospinal fluid (CSF) | Bilirubin - Total |
| Chemical pathology - Investigation of malabsorption | Faeces; Urine | Reducing substances |
| Chemical pathology - Trace element analysis | Blood | Cadmium; Lead |
| Serum | Copper; Zinc | |
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Cerebrospinal fluid (CSF) | Oligoclonal bands |
| Faeces | Calprotectin | |
| Other body fluids | β2-Transferrin | |
| Plasma | Cryofibrinogen | |
| Serum | Free light chains | |
| Protein classes | ||
| Cryoglobulins | ||
| Urine | Detection of Bence Jones proteins |
Special Haematology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Haematology - Assessment of haemolysis or metabolic enzymes (red cell enzyme assays) | Blood | Glucose-6-phosphate dehydrogenase (G6PD) |
| Haematology - Examination of blood films by special staining | Blood | Heinz bodies |
| Malaria | ||
| Haematology - Investigation of haemolysis | Urine | Haemoglobin (Hb); Haemosiderin |
| Immunopathology - Characterisation of leucocyte surface antigens (including immunophenotyping) | Blood; Bone marrow; Cerebrospinal fluid (CSF); Disaggregated tissues specimen; Serous fluid | 7-Aminoactinomycin (7-AAD); Anti-D; CD10; CD103; CD117; CD11c; CD13; CD138; CD14; CD15; CD16; CD19; CD1a; CD2; CD20; CD200; CD22; CD23; CD235a; CD24; CD25; CD3; CD30; CD33; CD34; CD38; CD4; CD40; CD41; CD45; CD5; CD56; CD57; CD59; CD61; CD64; CD7; CD79a; CD8; CD95; Cytokeratin; Eosin-5-maleimide; Epithelial antigen; FMC7; Fluorescein-labelled proaerolysin (FLAER); Gamma 1; HLA-B27; HLA-DR antigen; Haemoglobin F (HbF); Kappa light chains; Lactoferrin; Lambda light chains; Myeloperoxidase; T-cell receptor aβ (TCRab); T-cell receptor γδ (TCRgd); Terminal deoxynucleotidyl transferase (TdT) |
| Immunopathology - Procedures related to the collection, processing, storage and issue of human haemopoietic progenitor cellsProducts received from Oncology Outpatient Unit, Royal Hobart Hospital (18802-20933) and WP Holman Clinic, Launceston General Hospital (18803-20934) | Cord blood; Donor lymphocytes; Haemopoietic progenitor cells | Processing; Storage (includes freezing/thawing) |
| Microbiology - Parasitology - Detection of ova, cysts and parasites | Blood | Malaria |
Specialist Clinic
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
Telstra Building
ISO 15189 (2022)
Human Pathology
Medicare expiry date
17 Jan 2028
Last Activity Date
07 Aug 2024
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
The only data displayed is that deemed relevant and necessary for the clear description of the activities and services covered by the scope of accreditation.
Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.
Accreditation No.
3036
Site No.
3029
Print date
26 Apr 2025
END OF SCOPE